|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 88.89 | 103.80 | 0.54 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
6505.50
|
|
|
52-Week-Low (Rs.)
|
4383.40
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Operational & Financial Ratios | | | | | | Earnings Per Share (Rs) | 156.83 | 97.55 | 131.39 | 176.76 | 76.95 | CEPS(Rs) | 212.24 | 146.48 | 181.57 | 224.24 | 123.97 | DPS(Rs) | 40.00 | 30.00 | 25.00 | 25.00 | 20.00 | Book NAV/Share(Rs) | 1,220.20 | 1,093.32 | 1,013.05 | 907.83 | 759.31 | Tax Rate(%) | 32.42 | 27.01 | 28.46 | -5.83 | 24.90 | Margin Ratios | | | | | | Core EBITDA Margin(%) | 24.85 | 18.01 | 23.50 | 24.22 | 21.31 | EBIT Margin(%) | 22.89 | 15.70 | 23.24 | 23.83 | 16.54 | Pre Tax Margin(%) | 22.79 | 15.44 | 22.89 | 23.42 | 16.01 | PAT Margin (%) | 15.40 | 11.27 | 16.38 | 24.79 | 12.02 | Cash Profit Margin (%) | 20.85 | 16.92 | 22.63 | 31.45 | 19.37 | Performance Ratios | | | | | | ROA(%) | 10.48 | 7.08 | 10.87 | 16.73 | 7.68 | ROE(%) | 13.57 | 9.26 | 13.69 | 21.22 | 10.50 | ROCE(%) | 18.91 | 11.68 | 17.81 | 18.58 | 12.49 | Asset Turnover(x) | 0.68 | 0.63 | 0.66 | 0.68 | 0.64 | Sales/Fixed Asset(x) | 1.19 | 1.12 | 1.18 | 1.19 | 1.12 | Working Capital/Sales(x) | 1.84 | 1.93 | 2.09 | 2.00 | 1.82 | Efficiency Ratios | | | | | | Fixed Capital/Sales(x) | 0.84 | 0.89 | 0.85 | 0.84 | 0.89 | Receivable days | 99.35 | 114.34 | 119.20 | 128.69 | 136.06 | Inventory Days | 68.76 | 78.14 | 68.49 | 64.77 | 66.51 | Payable days | 115.51 | 102.62 | 99.93 | 100.38 | 119.58 | Valuation Parameters | | | | | | PER(x) | 29.47 | 44.14 | 34.37 | 17.63 | 36.05 | PCE(x) | 21.77 | 29.39 | 24.87 | 13.90 | 22.38 | Price/Book(x) | 3.79 | 3.94 | 4.46 | 3.43 | 3.65 | Yield(%) | 0.87 | 0.70 | 0.55 | 0.80 | 0.72 | EV/Net Sales(x) | 4.50 | 4.99 | 5.60 | 4.49 | 4.42 | EV/Core EBITDA(x) | 15.90 | 23.35 | 18.97 | 14.73 | 18.52 | EV/EBIT(x) | 19.68 | 31.75 | 24.08 | 18.85 | 26.74 | EV/CE(x) | 3.72 | 3.50 | 4.11 | 2.82 | 2.89 | M Cap / Sales | 4.54 | 4.97 | 5.63 | 4.37 | 4.33 | Growth Ratio | | | | | | Net Sales Growth(%) | 17.75 | 7.91 | 12.65 | 11.53 | 13.53 | Core EBITDA Growth(%) | 56.24 | -21.88 | 9.00 | 42.34 | 65.47 | EBIT Growth(%) | 71.67 | -27.11 | 9.89 | 60.66 | 131.31 | PAT Growth(%) | 60.97 | -25.76 | -25.57 | 129.99 | 125.31 | EPS Growth(%) | 60.77 | -25.76 | -25.66 | 129.72 | 125.31 | Financial Stability Ratios | | | | | | Total Debt/Equity(x) | 0.00 | 0.12 | 0.07 | 0.10 | 0.08 | Current Ratio(x) | 3.08 | 2.23 | 2.40 | 2.42 | 2.90 | Quick Ratio(x) | 2.40 | 1.68 | 1.78 | 1.89 | 2.25 | Interest Cover(x) | 229.76 | 59.52 | 66.44 | 59.07 | 30.94 | Total Debt/Mcap(x) | 0.00 | 0.03 | 0.02 | 0.03 | 0.02 |
|
|
|
|
|
|